Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

Background— Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden death in the young, although not all patients eligible for sudden death prevention with an implantable cardioverter-defibrillator are identified. Contrast-enhanced cardiovascular magnetic resonance with late gadolinium enhancement (LGE) has emerged as an in vivo marker of myocardial fibrosis, although its role in stratifying sudden death risk in subgroups of HCM patients remains incompletely understood. Methods and Results— We assessed the relation between LGE and cardiovascular outcomes in 1293 HCM patients referred for cardiovascular magnetic resonance and followed up for a median of 3.3 years. Sudden cardiac death (SCD) events (including appropriate defibrillator interventions) occurred in 37 patients (3%). A continuous relationship was evident between LGE by percent left ventricular mass and SCD event risk in HCM patients (P=0.001). Extent of LGE was associated with an increased risk of SCD events (adjusted hazard ratio, 1.46/10% increase in LGE; P=0.002), even after adjustment for other relevant disease variables. LGE of ≥15% of LV mass demonstrated a 2-fold increase in SCD event risk in those patients otherwise considered to be at lower risk, with an estimated likelihood for SCD events of 6% at 5 years. Performance of the SCD event risk model was enhanced by LGE (net reclassification index, 12.9%; 95% confidence interval, 0.3–38.3). Absence of LGE was associated with lower risk for SCD events (adjusted hazard ratio, 0.39; P=0.02). Extent of LGE also predicted the development of end-stage HCM with systolic dysfunction (adjusted hazard ratio, 1.80/10% increase in LGE; P<0.03). Conclusions— Extensive LGE measured by quantitative contrast enhanced CMR provides additional information for assessing SCD event risk among HCM patients, particularly patients otherwise judged to be at low risk.

[1]  Giuseppe Limongelli,et al.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.

[2]  M. Maron Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters. , 2013, JACC. Cardiovascular imaging.

[3]  Harry Rakowski,et al.  Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. , 2013, JACC. Cardiovascular imaging.

[4]  B. Maron,et al.  Hypertrophic cardiomyopathy – Authors' reply , 2013, The Lancet.

[5]  M. Link,et al.  Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[6]  R. Fattori,et al.  Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis , 2012, BMJ Open.

[7]  M. Pencina,et al.  Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.

[8]  C. Kramer,et al.  Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. , 2012, JACC. Cardiovascular imaging.

[9]  M. Maron,et al.  Clinical Utility of Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy , 2012, Journal of Cardiovascular Magnetic Resonance.

[10]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[11]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[12]  Pierre Croisille,et al.  Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.

[13]  Vivek Muthurangu,et al.  Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. , 2011, JACC. Cardiovascular imaging.

[14]  R. Kwong,et al.  Measuring myocardial scar by CMR. , 2011, JACC. Cardiovascular imaging.

[15]  P. Core Hypertrophic cardiomyopathy:quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging , 2011 .

[16]  M. Cheitlin,et al.  Myocardial Scar Visualized by Cardiovascular Magnetic Resonance Imaging Predicts Major Adverse Events in Patients With Hypertrophic Cardiomyopathy , 2011 .

[17]  C. Kramer,et al.  Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance: the future looks bright. , 2010, Journal of the American College of Cardiology.

[18]  W. Manning,et al.  Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[19]  Lidia Chojnowska,et al.  Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. , 2010, European journal of radiology.

[20]  Stefan O Schoenberg,et al.  Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[21]  V. Positano,et al.  Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. , 2010, The American journal of cardiology.

[22]  B. Maron Contemporary Reviews in Cardiovascular Medicine Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2010 .

[23]  M. Sheppard,et al.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .

[24]  A. Tajik,et al.  Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[25]  D. Pennell,et al.  Cardiovascular Magnetic Resonance , 2019, Cardiac CT, PET & MR.

[26]  N. Smedira,et al.  Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. , 2009, Journal of the American College of Cardiology.

[27]  W. Manning,et al.  Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. , 2009, Journal of the American College of Cardiology.

[28]  R. Bonamini,et al.  Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features. , 2009, Circulation Cardiovascular Imaging.

[29]  J. Moon,et al.  The emerging role of cardiovascular magnetic resonance in refining the diagnosis of hypertrophic cardiomyopathy , 2009, Nature Clinical Practice Cardiovascular Medicine.

[30]  S. Prasad,et al.  Cardiovascular magnetic resonance of cardiomyopathies , 2009, Current cardiology reports.

[31]  M. Josephson,et al.  A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. , 2008, Journal of the American College of Cardiology.

[32]  Warren J Manning,et al.  Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy , 2008, Circulation. Heart failure.

[33]  W. Roberts,et al.  Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. , 2008, The American journal of cardiology.

[34]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[35]  Mario J. Garcia,et al.  Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study , 2008, The International Journal of Cardiovascular Imaging.

[36]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[37]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[38]  C. Rochitte,et al.  The emerging role of MRI in the diagnosis and management of cardiomyopathies , 2006, Current cardiology reports.

[39]  M. Borggrefe,et al.  CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis. , 2005, European heart journal.

[40]  Robert G. Hauser,et al.  Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.

[41]  B. Maron,et al.  Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[42]  Dudley J Pennell,et al.  The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[43]  C. Semsarian,et al.  Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[44]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[45]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[46]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[47]  Raymond J Kim,et al.  Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? , 2003, Journal of the American College of Cardiology.

[48]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[49]  B. Maron Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[50]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[51]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[52]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[53]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[54]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[55]  W. Roberts,et al.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.

[56]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[57]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.

[58]  D TEARE,et al.  ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.